Managing Brain Metastases in HER2+  Breast Cancer: Second-Line Treatment Decisions Panelists discuss how the presence of brain metastases influences treatment decisions in HER2-positive (HER2+) breast cancer, highlighting the DESTINY-Breast12 trial demonstrating trastuzumab deruxtec...

Navigating treatment sequencing in HER2+ metastatic breast cancer is critical; especially when brain mets are involved. Second-line decisions change everything. Stay evidence-based. #TCSC #BreastCancer #HER2Positive #Oncology #CancerCare #BrainMetastase

www.onclive.com/view/managin...